Execution Under Pressure: What Building a FemTech Company Reveals About Leadership, Capital, and Discipline

In early-stage healthcare companies, progress is rarely linear. Timelines stretch. Milestones move. Investors grow impatient. Teams lose focus.

Occasionally, however, a company compresses time.

Recently, I sat down with Roswitha Verwer, founder of YONE, together with Károly Szántó of UniPrisma Venture Studio. What I wanted to understand was simple: how did a young femtech company manage to complete most of its next year’s roadmap within six months?

The answer was not luck. It was execution.

For leaders building companies in regulated industries, there are lessons here that extend far beyond femtech.

Speed Is a Leadership Decision

When Roswitha updated us on YONE’s progress, the facts were clear. Since closing investment in August, the company has advanced through TRL 2 and 3 and is already in Phase 1 of TRL 4. A second scientific publication is finalized. The IP roadmap is moving forward. The prototype is under development. Clinical preparation is on track.

Most founders underestimate timelines. In biotech and medtech, delays are the norm.

Delivering ahead of schedule requires a specific mindset. Roswitha described it plainly: deadlines are not targets to meet. They are targets to beat. If something goes wrong, there must be a buffer.

This is not optimism. It is risk management.

In clinical research, I have seen too many projects fail not because the science was weak, but because operational friction was ignored until it became structural damage. The difference here is anticipation. If communication slows, it is addressed. If vendors hesitate, contracts are adjusted. If benchmarks are unclear, they are defined in writing.

Acceleration is rarely about working faster. It is about removing uncertainty before it compounds.

Communication Is Infrastructure

Founders often assume that signing a vendor contract secures execution. It does not.

YONE encountered friction in laboratory communication. Reports were critical to milestone progression, yet response times did not reflect urgency. Instead of accepting delays, the team implemented structural changes: mandatory 24-hour response clauses, designated project managers, and weekly risk-mitigation calls.

This may appear procedural. It is not.

In highly regulated industries, communication is operational infrastructure. If feedback loops are slow, decisions stall. If responsibilities are unclear, risk multiplies.

Many early-stage companies focus on product and capital but neglect governance discipline. Strong governance does not slow startups. It protects them.

Building a Global Team Without Diluting Standards

YONE operates with a global team across time zones. That alone introduces complexity. Alignment becomes fragile when people do not share physical space.

Roswitha’s approach is deliberate. Culture is documented. Policies are explicit. Every new hire undergoes a three-month evaluation period. Weekly calls exist not only across divisions, but also individually. Legal, finance, medical, and regulatory each have defined cadence.

Experience matters, but personality alignment matters more.

In my own companies, I have seen that competence without cultural alignment creates long-term drag. Especially in startups, where margins for error are narrow, cohesion is not optional.

The most interesting element was not the structure. It was a professional identity. The team is trained to represent the company at a level comparable to organizations that have existed for decades. That reputation is already visible externally.

Professionalism is a competitive advantage. It signals seriousness to partners and investors.

The Hard Part: Meritocracy in Practice

Most leadership conversations celebrate vision and resilience. Few discuss the uncomfortable part: performance management.

Roswitha is explicit. If KPIs are repeatedly missed, a direct conversation follows. Advisors, executives, junior staff, no one is exempt. Data precedes discussion. Assumptions are avoided. Emotions are separated from business.

This is difficult, particularly for a young female founder navigating male-dominated investor rooms and senior advisory boards.

Yet meritocracy requires clarity. Numbers reduce ambiguity. Calm confrontation preserves respect.

In my experience, failure to address underperformance early is one of the most expensive mistakes founders make. It erodes culture silently.

Training also plays a role. YONE invests in communication training for junior team members so that professionalism is consistent across every touchpoint. Reputation is not built only by founders. It is built by every email and every call.

Capital Is the External Variable

Execution can be managed internally. Capital cannot.

YONE is currently raising an additional 600,000 euros to complete TRL 4 and finalize the prototype. The seed round is targeted for the summer next year. Clinical trials are planned for next year.

This is where execution meets market reality.

As Károly Szántó pointed out, fundraising in medtech is generally challenging. For femtech and female founders, the difficulty increases. Prejudice exists. Investor attention skews toward either very early concepts or post-clinical assets. Companies in between face a narrow funding corridor.

There is another structural challenge. Many investors express support for female founders or femtech innovation. Fewer deploy capital.

The paradox is visible. When Roswitha secures a meeting, she performs strongly. The barrier is access.

In some early meetings, dynamics shifted simply by including a male colleague in the room. The pitch remained identical. Perception changed.

These realities are uncomfortable but real.

For founders, recognizing bias is not enough. Strategy must adapt. Advisory boards are constructed intentionally. Investors are selected based on alignment, not logos.

Choosing the Right Co-Investors

Not all capital is equal.

In our discussion about ideal co-investors, one theme was dominant: values.

High-net-worth individuals who invest because they believe in a cause behave differently than purely transactional investors. Certain family offices prioritize legacy and long-term impact. They are patient. They understand that building medical innovation requires time.

In regulated healthcare, co-investors must understand development cycles, risk mitigation, and regulatory pacing. Capital without sector literacy can destabilize governance.

For YONE, and for many early-stage healthcare companies, the goal is not simply to close a round. It is to close with partners who strengthen execution rather than distract from it.

Leadership Maturity Under Pressure

One of the most important shifts Roswitha described was personal.

Earlier in her journey, she overanalyzed difficult conversations. She carried emotional weight from investor dynamics. Under pressure, especially in male-dominated spaces, hesitation can grow.

Now, she separates emotion from decision. If alignment is absent, the answer is no. If investment terms are not feasible, they are declined.

This evolution is critical. Leadership maturity is not about confidence in public. It is about clarity in private decisions.

When significant capital and patient impact are at stake, hesitation becomes risk.

Beyond One Company

The broader question remains: why is it structurally harder for female-led femtech companies to raise capital?

Part of the answer is historical. Healthcare investment has long been male-dominated. Part is cultural discomfort around women’s health topics. Part of the pattern-recognition bias in venture capital is that investors fund what resembles past winners.

However, change is visible. Regulatory awareness is increasing. Institutional investors are beginning to recognize the economic opportunity in underserved markets.

The responsibility now lies with investors willing to act rather than signal.

As Károly noted, bravery matters. Those who engage deeply, understand execution speed, and evaluate traction objectively will position themselves advantageously as negotiation power shifts toward high-performing teams.

The Case for an Integrated Model

In my own investment strategy, I do not operate as a passive financial investor. I combine clinical expertise, operational infrastructure, and capital. When investors have domain experience and skin in the game, the discussion changes.

Early alignment with operators who understand regulatory and clinical realities reduces risk. It creates discipline in study design, regulatory strategy, and milestone pacing.

This integrated model is not theoretical. It is visible in companies that compress timelines responsibly.

A Model Worth Studying

YONE is still early. Fundraising remains challenging. Clinical execution is ahead but not complete.

Yet within six months, the company demonstrated that disciplined communication, cultural alignment, performance management, and value-driven capital strategy can materially alter trajectory.

For healthcare executives and investors, the lesson is clear.

Innovation is not primarily constrained by science. It is constrained by execution discipline and capital alignment.

When those two variables are managed deliberately, time itself becomes negotiable.

And in healthcare, time is not a luxury. It is an impact.